Accomplished by using short-wave
ultraviolet-C (UV-C) light as a germicidal to destroy viruses, bacteria and other pathogens that can linger on surfaces and hide in shadows.
One piece of equipmnet can disinfect an average-sized patient room in about 8 minutes and is deployed after a room is sanitized with standard techniques and cleaning products.
In Canandaigua, New York a nearly 6 foot tall and wielding 20 vertical fluorescent bulbs, the R-D Rapid Disinfector robot is a formidable fighter in the war against germs.
This UV disinfecting robot is The R-D Rapid Disinfector — developed by a Rochester, New York firm, Steriliz LLC, and is manufactured locally.
Thompson Hospital and the M.M. Ewing Continuing Care Center have begun using this automated disinfecting machine throughout the institutions to help reduce the risks of illness and infections for patients, residents, visitors and staff.
The Disinfector uses short-wave ultraviolet-C (UV-C) light as a germicidal to destroy viruses, bacteria and other pathogens that can linger on surfaces and hide in shadows. This machine can disinfect an average-sized patient room in about 8 minutes and is deployed after a room is sanitized with standard techniques. It is remotely controlled by an associate from Environmental Services.
The UV-C light fills the entire room, reaching and disinfecting areas that human hands might miss. No one is allowed inside the room when the lights are working. This no-touch cleaning system gets rid of some of the most dangerous and difficult-to-destroy bacteria, including Clostridium difficile (C. diff). Disinfectants work on the surface of non-living objects by destroying the cell wall of harmful microbes or interfering with their metabolism.
“This technology, added on to normal, regular, manual environmental cleaning, gives me a sense of ease that we are doing all we can to keep our environment clean and our patients safe,” said Thompson Health Director of Infection Prevention Michelle Vignari. “We are just now starting to see published literature supporting that the addition of UV-C technology in hospitals actually does correlate with a reduction of healthcare-acquired infections.”
This state-of-the-art robot monitors the entire disinfection process. Wireless sensors measure, record and report on UV-C light dosages delivered to specific areas in real time. The machine can be paused and repositioned to maximize efficiency, including targeting shadowed areas. The Disinfector shuts off automatically once the sensors indicate that enough UV-C light has been emitted to kill the germs.
“In a day of delivering high-reliability care, I felt very strongly that we needed a technology that we could measure and evaluate its performance,” Vignari said.
Hospital staff like the Disinfector too.
“It is pretty simple to use and seems to be working great,” said Stephanie Fowler of Environmental Services, who activates the robot after a room is cleaned with traditional methods.
The R-D Rapid Disinfector was developed by a Rochester firm, Steriliz LLC, and is manufactured locally. The Disinfector uniquely provides FDA-patented wireless sensors to measure the amount of UV-C light delivered to an area and real-time online data access and reports. Since being tried in four Rochester hospitals in 2011, several hundred of these Disinfectors are now being used in hospitals, care homes, disaster centers and government installations worldwide.
Steriliz is recognized as a world leader in UV-C disinfection.
“Improving the health and safety of patients is a blessed opportunity,” said CEO and President Sam Trapani. “The potential market for the company’s product is large and we are experiencing a high growth curve.”
To read the article in its entirety please click on the link below:
Laguna Beach, CA – In 2017 Mission Hospital, a member of the St. Joseph Hoag Health network, has added a new layer of proactive protection against the spread of infections in its facility. In addition to stringent manual cleaning processes by the facility’s environmental care services (EVS) team, Mission Hospital has adopted Tru-D SmartUVC, a UV disinfection robot, to provide terminal room disinfection once the EVS staff performs manual cleaning protocols.
Since its founding, Mission Hospital continues to develop new programs and services to meet the ever changing needs of the community. Mission Hospital has also had a long-standing partnership with CHOC Children’s to provide pediatric services. In 2009, Mission Hospital expanded its geographic footprint to include south Orange County’s coastline by acquiring Mission Hospital Laguna Beach, CA . Improved patient outcomes and the highest quality of care have always been at the core of Mission Hospital, and Tru-D demonstrates the facility’s dedication to proactive, excellent patient and staff care.
“Mission Hospital is committed to providing the highest level of patient care possible in the cleanest health care environment possible,” said Tarek Salaway, Chief Executive at Mission Hospital. “The investment of this technology is one of many ways that we are working to safeguard the well-being of every single patient who walks through our doors and protect the integrity of our health care environment.”
To read the article in its entirety – click on the link provided below:
About Tru-D SmartUVC Tru-D SmartUVC is the only UV disinfection device backed by a CDC-funded, randomized clinical trial. Using Sensor360 technology, Tru-D compensates for room variables and delivers the precise, calculated dose of UVC needed for terminal room disinfection. For information and links to independent studies on Tru-D, visit Tru-D.com
About Mission Hospital As a part of the St. Joseph Hoag Health network of care, Mission Hospital was founded in Mission Viejo in 1971 and has since grown to a two-campus facility with 552 beds and approximately 2,500 employees. Mission Hospital, a ministry of St. Joseph Health, has been serving the greater needs of the community for more than 40 years, improving the quality of life in the communities it serves in the tradition of the Sisters of St. Joseph of Orange. Mission Hospital in Mission Viejo is an acute care, full-service facility providing advanced health care services and diagnostic care to south Orange County and is the only designated trauma center in South Orange County. Mission Hospital Laguna Beach (MHLB) provides South Orange County coastal communities with 24-hour emergency and intensive care as well as medical-surgical/telemetry services. Mission Hospital offers specialty care in cardiovascular, neuroscience and spine, orthopedics, women’s services, urology, oncology, mental health & wellness, head and neck and other key specialties. CHOC Children’s at Mission Hospital is a 48-bed facility that is the area’s only dedicated pediatric hospital for more than two decades. Fully accredited by The Joint Commission and designated as a Magnet hospital by the American Nurses Credentialing Center for nursing excellence, Mission Hospital has received numerous awards and recognition for its high quality of care. For more information, visit http://www.mission4health.com
The only robot in the Verdugo region that zaps away unwanted bacteria and viruses from hospital rooms arrived at USC-Verdugo Hills Hospital two weeks ago.
The Xenex robot emits a pulsating, bright white UV-C light — which is a short, wavelength, ultraviolet light that can save lives. Once surfaces are exposed to the robot’s rays, harmful bacteria and viruses die, greatly reducing the odds patients will be infected with hospital-acquired infections, including those caused by superbugs such as methicillin-resistant Staphylococcus aureus, known as MRSA.
USC-Verdugo Hills Hospital employees joined Xenex employees at Fremont Elementary School, where they showcased the $100,000 machine in teacher Mallory Kane’s sixth-grade classroom, the same place where Keith Hobbs, chief executive of Verdugo Hills Hospital, was a sixth-grader in 1979. “There’s no other place that I would rather be than to come back to my alma mater and share this R2D2, bug-zapping machine with you guys,” Hobbs said.
The Xenex robot pulses UV-C light 67 times per second, and hospital staff take precautions when they operate it because the light can harm their eyes.
“This is not any light bulb in your house,” said Mary Virgallito, director of patient safety for the hospital. “It’s actually filled with a gas called xenon.”
Virgallito said hospital employees manually clean rooms before they activate Xenex. It takes the robot about 15 minutes to clean a patient’s room, and 20 minutes to disinfect an operating room.Hobbs said mothers ask if they can borrow the robot to disinfect their own homes, and Kane suggested it would be helpful in the classroom. Over the past several weeks, many of her students missed school because they were sick.
Jeff Mamalakis, business development manager for Xenex, volunteered to disinfect Kane’s room when school let out. The space would be left with a scent as if lightning had just struck, Virgallito said. The impromptu high-tech, germ-cleansing session was a dream come true for Kane.
“In sixth grade, the curriculum moves so quickly that even missing one day puts kids so far behind,” Kane said. “Having our classroom disinfected every day would be a dream come true. My kids would be here, everyone would be happy, no one would have to miss school.”
To Read the article in its entirety please click on the following link:
On the other hand, the benefit of what Anderson called “enhanced terminal disinfection” varied among the four pathogens, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococcus (VRE), multidrug-resistant (MDR) acetinobacter, and Clostridium difficile.
What was the BETR-D Study?
The BETR-Disinfection study was performed over 28 months in 9 study hospitals from 4/2012 to 7/2014.
Each hospital used four strategies for terminal room disinfection in a randomized sequence.
Each strategy was used for 7-month study arms, including a 1 month wash-in period.
Two of these strategies used a UV-C emitting device.
Standard cleaning involved the use of a quaternary ammonium (reference group A). Three enhanced cleaning strategies were evaluated and compared to the reference: quaternary ammonium + UV-C (B), bleach (C), and bleach + UV-C (D).Of note, bleach was used for daily and terminal disinfection of all known C. difficile rooms, regardless of study arm.
Study cleaning strategies were employed in seed rooms, defined as a room containing a patient on contact precautions for infection or colonization due to the following 4 target MDROs was discharged: MRSA, VRE, C. difficile, or MDR Acinetobacter.
The next patient in the room was considered an exposed patient.
Primary outcome was the clinical incidence of all target MDROs in patients exposed for at least 24 hours, defined as the first positive culture of a MDRO a) during exposure to the seed room, if positivity occurred ≥48 hr post-admission to the seed room, or b) in the 90 days following seed room exposure for MRSA, VRE, and MDR-Acinetobacter and 28 days for C. difficile.
Rates were calculated as outcome/10,000 exposure days using intention-to-treat and per protocol principles
To read the study Abstract in its entirety please click on the following link:
A study of a large cluster-randomized trial, adding bleach to the standard quaternary ammonium cleaning significantly reduced the risk of transmission of four organisms that cause healthcare-associated infections
A Cluster Randomized, Multicenter Crossover Study with 2×2 Factorial Design to Evaluate the Impact of Enhanced Terminal Room Disinfection on Acquisition and Infection Caused by Multidrug-Resistant Organisms (MDRO)
The goal was to see if they could reduce the overall incidence of the targeted pathogens among patients using a room immediately after a patient known to be colonized or infected by one of the four occupied it. A second primary endpoint was the effect on C. difficile.
He noted that all rooms in which a patient had had C. difficile were cleaned with bleach, so the comparisons were actually between quaternary ammonium and bleach and the same approach adding UV light.
All told, the study had 23,272 patients potentially exposed to a pathogen — they spent at least 24 hours in one of the “seed” rooms where the previous patient had been identified as having one of the pathogens.
Patients in seed rooms became cases if they developed colonization or infection by the pathogens linked to their rooms, as long as they had no history of the pathogen in the previous year and no evidence of community acquisition, he said.
In the four arms, Anderson reported:
There were 115 cases in 22,426 exposure days in the standard cleaning arm, for a rate of 51.3 cases per 10,000 exposure days.
In the arm adding ultraviolet, there were 76 cases in 22,389 exposure days for a rate of 33.9
When bleach was added, there were 101 cases in 24,261 exposure days, for a rate of 41.6.
And when both bleach and UV were added, there were 131 cases in 28,757 exposure days, for a rate of 45.6.
The reductions, compared with standard cleaning, were 30%, 15% and 9%, respectively, but only the addition of UV light to quaternary ammonium reached statistical significance (P=0.036).
There were too few cases of MDR acetinobacter to quantify, he said, but it was possible to judge the effect of the various interventions on the other three pathogens.
For MRSA, adding UV light to quaternary ammonium reduced the risk of transmission by 22%, but the difference from standard cleaning fell short of statistical significance. The other two interventions made no difference.
For VRE, on the other hand, all three test strategies reduced the risk of transmission by about 60% — 59% for UV, 57% for bleach, and 64% for bleach plus UV. However, Anderson said, the UV arm was just short of statistical significance, while the other two were significantly different from standard cleaning (P=0.049 and P=0.003, respectively).
But adding UV light to bleach in rooms linked to C. difficile had no effect, Anderson reported.
Note: Not all UV disinfecting products are the same– in the way they are scientifically developed, manufactured, and utilized in the healthcare industry. It is favorable for Hospital and Healthcare facility decision-makers to ask some tough questions when it comes to evaluating UV technologies. The gold standard for assessing new technologies is to evaluate peer-reviewed literature published and also cited in The Lancet publication. Please click on the The Lancet article link below to retrieve additional information focused on the BETR-D study.
31 226 patients were exposed; 21 395 (69%) met all inclusion criteria, including 4916 in the reference group, 5178 in the UV group, 5438 in the bleach group, and 5863 in the bleach and UV group. 115 patients had the primary outcome during 22 426 exposure days in the reference group (51·3 per 10 000 exposure days). The incidence of target organisms among exposed patients was significantly lower after adding UV to standard cleaning strategies (n=76; 33·9 cases per 10 000 exposure days; relative risk [RR] 0·70, 95% CI 0·50–0·98; p=0·036). The primary outcome was not statistically lower with bleach (n=101; 41·6 cases per 10 000 exposure days; RR 0·85, 95% CI 0·69–1·04; p=0·116), or bleach and UV (n=131; 45·6 cases per 10 000 exposure days; RR 0·91, 95% CI 0·76–1·09; p=0·303) among exposed patients. Similarly, the incidence of C difficile infection among exposed patients was not changed after adding UV to cleaning with bleach (n=38 vs 36; 30·4 cases vs 31·6 cases per 10 000 exposure days; RR 1·0, 95% CI 0·57–1·75; p=0·997).
The BETR-D study was supported by the CDC
Listen to Deverick J. Anderson, MD, MPH, FIDSA, FSHEA discuss UV Intervention Addressing C. difficile and Other Pathogens July 2016
On November 21, 2016 3M shared a press release introducing the
C.diff. Solution Tablets – EPA Registered to Kill C.diff. Spores in 4 minutes.
When most people think of hospitals, they imagine a safe, clean environment where patients can comfortably receive treatments in an effort to get healthy. However, in reality, hospitals can pose potential risks to both patients and staff, through the threat of infections caused by pathogens such as MRSA, E. coli and C. difficile (C. diff.).
Remarkably, C. diff contributes to nearly 29,000 deaths every year – almost matching the number of deaths caused by influenza.[i] Despite the prevalence of this organism, prevention and containment pose numerous challenges as the spores can survive for weeks on a large variety of surfaces.
To combat the rise of C. diff infections at hospital facilities, 3M recently launched 3MC. diff Solution Tablets, providing a proven, effective alternative to bleach and peracetic acid disinfectants.
Now available for use in the U.S., the new product delivers on effectiveness, efficiency and value, by providing the following:
EPA-registered to kill diff spores in four minutes
Effective against Norovirus
Safer than bleach and peracetic acid, featuring an NFPA rating of 0,0,0 with no personal protective equipment required at use dilution
In-use pH of 5.5 to 6.5, which is closer to neutral than bleach or peracetic acid
Dissolves in approximately three minutes with a mild chlorine smell
Tablets are available in two sizes for use in large and small containers
The product can be applied with a cloth, wipe, mop, or coarse trigger sprayer, and will not bind to common wiping media
Costs significantly less than ready-to-use bleach
Yields a three-year shelf life in sealed packets, and seven-day shelf life when diluted and stored in a closed container
“We are excited to provide our customers with an effective solution for the battle against C. diff,” said Adrian Cook, product marketer for chemicals at 3M Commercial Solutions Division. “The reduction and prevention of infections is an important focus for our customers and we look forward to continuing our work in ensuring safe environments.”
In addition to the new product launch, 3M Commercial Solutions Division also announced the expansion of its Flow Control System product line through the introduction of four additional chemical offerings:
3M Quat Disinfectant Cleaner Concentrate 5A EPA-registered disinfectant cleaner for use in hospitals. Kills HIV-1, MRSA, VRE, herpes simplex I and II and other pathogens. Rinse-free, pleasant fragrance. 0.5 gallon concentrate bottle yields 107 ready-to-use gallons. 4/case.
3M Neutral Quat Disinfectant Cleaner Concentrate 23A EPA-registered disinfectant cleaner kills HIV-1, MRSA, VRE, herpes simplex I and II, and other pathogens. Rinse-free, low foaming, neutral pH formula. 0.5 gallon concentrate bottle yields 100 ready-to-use gallons. 4/case.
Scotchgard Pretreatment Cleaner Concentrate 28A Hard-working cleaner for heavily soiled areas of colorfast carpet. Use as a pre-spray prior to extraction or shampooing to loosen soils and stains. 0.5 gallon concentrate bottle yields 26 ready-to-use gallons. 4/case.
3M Bathroom Cleaner Concentrate 44A Green Seal Certified bathroom cleaner. Removes soap scum and scale from bathroom surfaces. 0.5 gallon concentrate bottle yields 28 ready-to-use gallons. 4/case.
For more information about 3M C. diff Solution Tablets and the 3M Flow Control System, please visit www.3M.com/facility
All other trademarks listed herein are owned by their respective companies.
Source: 3M Company
*PLEASE NOTE – The C Diff Foundation does not endorse any products and/or clinical study in progress. All website postings are strictly for informational purposes only. Thank you.